Budesonide – bronhodilating medicinal product, which has an effective relaxing effect on bronchial smooth musculature, thus improving the airway. It is a synthetic analogue of the hormone of the adrenal cortex, which function is to regulate carbohydrate and mineral metabolism in tissues. Inhalation of the glucocorticoid Budesonide has a pronounced anti-allergic and anti-inflammatory effect. Effective complex Budesonide Formoterol maximally contributes to the reduction of clinical manifestations of bronchial asthma; it significantly increases the functionality of the bronchi and reduces the likelihood of exacerbations.
Anti-inflammatory action of Entocort is much more effective than that of cortisol. When the drug is injected into the blood, it inhibits the synthesis of PG and leukotrienes, actively inhibits the production of cytokines, does not allow inflammatory cells to migrate and become activated. It effectively increases the number of active beta-adrenergic receptors, thereby restoring the body’s response to bronchodilator beta-adrenergic substance after prolonged use.
Indications for use
Budesonide is a glucocorticoid drug agent, has a pronounced anti-inflammatory, anti-allergic and immunostimulating action, which allows its use in the treatment of bronchial asthma requiring maintenance therapy of corticosteroids and chronic obstructive pulmonary disease.
Entocort is not assigned if previously the patient has been diagnosed hypersensitivity to its components. It is not also used in the treatment of children up to 16 years.
It is used with extreme caution for the treatment of patients with an inactive form of TB, bacterial, fungal and viral lesions of the airway, during lactation and pregnancy.
The reception of the drug during pregnancy and breastfeeding
Entocort can be prescribed in the treatment of pregnant and nursing women, but only if the use exceeds the potential risk to the newborn or fetus. At the moment it is unknown whether the drug enters breast milk or not, and therefore, a breastfeeding woman needs to consider abandoning of lactation during the process of treatment.
Method of application and doses
The duration of treatment and dose of Entocort are prescribed individually be a doctor, based on symptoms and severity of the disease. The starting dose can vary from 1 to 2 mg / day in maintenance therapy; the patient should receive from 0.5 to 4 mg per day. When the necessary healing effect is achieved, the recommended dose should be reduced to a minimum, which will allow you to save a stable state of the patient. In those cases when it is necessary to obtain a quick therapeutic effect of the physician, the daily dose can be increased.
A single dose of Entocort at high doses is not accompanied by the development of symptoms of intoxication. However, the prolonged treatment with the drug in doses, which greatly exceed the recommended ones, may lead to systemic glucocorticosteroid effect on the type of Cushing, accompanied by suppression of adrenal function. The treatment with Entocort should be immediately stooped in case of identifying symptoms of hyperadrenocorticism.
Receiving Entocort may be accompanied by the development of cough, dry mouth, hoarseness, dysphonia, irritation of the mouth and throat, thrush, dryness of the mucous membrane of the pharynx, headaches and nausea.
In rare cases, the prolonged use of the drug in high doses may cause exhaustion of the adrenal cortex, hypertension, and hyperglycemia.